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The study was closed after the enrollment of the
first eight patients. There were four males and four
females with ages between 40 and 79. Performance
status was ECOG 0 in three patients, ECOG 1 in
four patients, and ECOG 2 in one patient. Two
patients received previous chemotherapy only and
six patients received both chemotherapy and irradia-
tion, including prophylactic brain irradiation in three
patients. Six patients were evaluable for response.
Two patients were removed from the study, the first
one due to allergy to filgrastim and the second one
due to refusal to continue on therapy after the first
cycle. Of the six evaluable patients, four patients
had stable disease and two had progressive disease.
Only one patient was able to complete six cycles
of chemotherapy. The most common grade 3 or 4
toxicity was neutropenia, occurring in five patients.
Other severe toxicities included thrombocytopenia
in three patients, anemia in one patient, dehydration
in two patients, fatigue in two patients, and malaise
in one patient. The lack of responses, poor accrual,
and increased toxicity leading to early withdrawal of
therapy in three of the four patients with ongoing
stable disease resulted in the premature closure of
the study for patient safety. It is unclear why this
treatment was so toxic and ineffective in our
population. The treatment was administered with
the lower doses and identical sequence to the regi-
men previously tested by Tkaczuk et al. [5]. The
only difference was the administration of docetaxel
on day 4 in the even cycles of the phase I study. The
lack of responses in the first patients may be
attributed at least in part to the significant toxicity
leading to dose delay and early discontinuation
from the study. The combination of topotecan and
docetaxel at the doses utilized in our study cannot be
recommended as a second-line therapy for patients
with chemotherapy-sensitive relapsed SCLC.
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Established systemic treatment choices for meta-
static neuroendocrine tumours (NETs) are
somatostatin analogues and alpha interferons
(IFN-alpha) both reducing the secretory activity
of the tumour. IFN-alpha also has an anti-prolif-
erative effect, inhibiting angiogenesis, blocking the
cell cycle, and stimulating apoptosis [1]. Che-
motherapy has limited value, used in NETs with
a high-proliferative index.
Angiogenesis has raised interest as a new target in
NETs. This interest is fuelled by the fact that NETs
are highly vascularised and vascular endothelial
growth factor (VEGF) and its receptors are present
[2]. We performed a study with IFN-alpha, 5-
fluorouracil (5-FU) and leucovorin in patients with
metastatic NETs because of the suggested synergis-
tic effects between 5-FU and IFN-alpha, and
promising results of this combination obtained by
others [3]. In this feasibility study, approved by the
Medical Ethical Committee, patients were treated
with IFN-alpha-2b (2.5 million U/day subcuta-
neously), and after 2 weeks, intravenous 5-FU
750 mg/m2 (day 2) and oral leucovorin 180 mg/day
(day 1 and 2) was added as a 2 weekly cycle.
The primary endpoint was toxicity, the secondary
endpoints included radiological and biochemical
response. In addition, serum was prospectively
stored for serum VEGF level measurements.
This study was prematurely closed after nine
patients because of side effects. After one cycle,
three patients had to stop, because of grade 3 fatigue
(n2) and heart failure (n1). Three additional
patients discontinued after respectively two, three
and four cycles because of arthritis and polyneuro-
pathy (n1) and grade 3-4 diarrhoea and fatigue
(n2). The remaining three patients completed 10,
19 and 20 cycles. Median survival was 22 months;
two patients are still alive after 144 months. All three
radiological evaluable patients experienced stable
disease lasting 584months.
Serum VEGF levels (R&D Systems, Minneapolis,
USA) decreased in seven of eight evaluable patients,
from a median level of 352 pg/ml (range 411
276 pg/ml) to 219 pg/ml (range 18938 pg/ml), a
median reduction of 40% in 88 days (median) (range
34462 days). This suggests an antiangiogenic effect
of the combination IFN-alpha and 5-FU. One study
showed that IFN-alpha alone did not reduce serum
VEGF levels in patients with carcinoid tumours,
although it did in another study (median reduction
33%) also decreasing VEGF mRNA expression in
liver metastases [1,4].
In the present study toxicity was conside-
rable. Next to the synergistic effect of this regime,
IFN-alpha also can potentiate the toxicity of 5-FU.
Four different dosages of 5-FU and IFN-alpha were
previously studied in patients with NETs, only the
regimen in a study of Andreyev and colleagues was
well tolerated in which 5-FU was given continuously
[3].
Bevacizumab, a monoclonal antibody against
VEGF was found to prolong progression free
survival compared to IFN-alpha in carcinoids while
sunitinib, a tyrosine kinase inhibitor, induced stable
disease in NETs [5,6]. Recently Zhang et al.
showed that bevacizumab inhibited tumour growth
in carcinoid xenograft, but at the same time up
regulation of VEGF transcription occurred as a
possible resistance mechanism [2]. During sunitinib
therapy elevated baseline serum VEGF also in-
creased, possibly due to resistance [7].
We conclude that this combination of 5-FU and
IFN-alpha is not feasible due to side effects.
However taken our observation of decreased
VEGF levels, less toxic modifications, e.g. 5-FU
given continuously or IFN-alpha combined with
capecitabine, an oral fluoropyrimidine prodrug,
in combination with one of the new antiangio-
genic drugs can be envisioned. Such a regime
might potentiate the effect of angiogenesis inhibi-
tors.
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Fatal tumor lysis syndrome after irinotecan/5-FU/folinic
acid/bevacizumab-containing therapy in a patient heavily
pretreated for metastatic colon cancer
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To the Editor
Tumor Lysis Syndrome (TLS) is a metabolic com-
plication usually arising from treatment of rapidly
proliferating and drug-sensitive neoplasms. It com-
prises a number of metabolic abnormalities such as
hyperkalemia, hyperuricemia, hypocalcemia and
precipitation of calcium phosphate or urate that
occur as a result of spontaneous or treatment-related
cell death. Commonly described in hematopoietic
malignancies, it occurs rarely in solid tumors [1].
We report on a patient with a ten-year history of
metastatic colon cancer who developed TLS after
having received 5th line irinotecan/5-FU/folinic acid/
bevacizumab-containing chemotherapy.
In March 1996 a 62-year old man was diagnosed
with colon cancer metastasized to the right lung.
From May 1996 to August 1997 he received 12
courses of 5-FU/folinic-acid (FA) based chemother-
apy (Mayo regimen) followed by surgical excision of
the remaining lung metastases. Recurrent lung me-
tastases were excised in June 1999 (1st relapse) and
June 2000 (2nd relapse). Tumor tissue was negative
for expression of epidermal growth factor receptor
(EGFR). From May 2002 to April 2003 eight courses
of capecitabine were administered for recurrent dis-
ease involving lungs and thyroid. A transient partial
remission was achieved. However, lung metastases
increased in size again and proved unresponsive to
two courses of 3rd line chemotherapy with oxaliplatin
and infusional 5-FU/FA (FOLFOX) given from
MayJuly 2003. Treatment was changed to irinote-
can/infusional 5-FU/FA in August 2003 with only one
course being applied because the patient experienced
severe diarrhea refractory to appropriate supportive
therapy. He was thus followed by observation from
November 2003 to January 2005. As lung metastases
increased in size again another cycle FOLFIRI was
administered. However, severe diarrhea resulted in
early termination of chemotherapy. Since the patient
experienced progressive lung disease FOLFIRI was
restarted under intensive supportive medication in
August 2005. After having responded to two courses
of FOLFIRI the patient requested termination of
chemotherapy. Radiation was administered for newly
diagnosed bone metastases in November 2005. The
patient received monthly bisphosphonates but re-
fused any further chemotherapy.
More than ten years after primary diagnosis of
metastatic colon cancer the patient presented with
progressive bone and lung metastases, the latter
involving almost the entire lung. Serum lactatdehy-
drogenase (LDH), uric acid and creatinine were
elevated at 493 U/l, 9.7 mg/dl and 1.4 mg/dl, respec-
tively. The patient received bevacizumab 5 mg/kg i.v.
(day 1) in combination with irinotecan (50 mg/m2
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